Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

The New World Symposium on Pulmonary Hypertension Guidelines: Should Twenty-One Be the New Twenty-Five?

Ruopp NF, Farber HW.

Circulation. 2019 Oct;140(14):1134-1136. doi: 10.1161/CIRCULATIONAHA.119.040292. Epub 2019 Sep 30. No abstract available.

PMID:
31567011
2.

Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.

Torres F, Farber H, Ristic A, McLaughlin V, Adams J, Zhang J, Klassen P, Shanahan W, Grundy J, Hoffmann I, Cabell C, Escribano SubĂ­as P, Sood N, Keogh A, D'Souza G, Rubin L.

Eur Respir J. 2019 Oct 10;54(4). pii: 1901030. doi: 10.1183/13993003.01030-2019. Print 2019 Oct.

PMID:
31391223
3.

Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases.

Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani HA, Hennessy B, Jansa P, Mehta S, Perchenet L, Pulido T, Rosenberg D, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Wei LJ, Channick R, Benza R.

Circ Cardiovasc Qual Outcomes. 2019 May;12(5):e005095. doi: 10.1161/CIRCOUTCOMES.118.005095.

PMID:
31109190
4.

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Humbert M, Farber HW, Ghofrani HA, Benza RL, Busse D, Meier C, Hoeper MM.

Eur Respir J. 2019 Jun 5;53(6). pii: 1802004. doi: 10.1183/13993003.02004-2018. Print 2019 Jun.

5.

Electronic cigarette use in youths: a position statement of the Forum of International Respiratory Societies.

Ferkol TW, Farber HJ, La Grutta S, Leone FT, Marshall HM, Neptune E, Pisinger C, Vanker A, Wisotzky M, Zabert GE, Schraufnagel DE; Forum of International Respiratory Societies.

Eur Respir J. 2018 May 30;51(5). pii: 1800278. doi: 10.1183/13993003.00278-2018. Print 2018 May.

PMID:
29848575
6.

Case 11-2018: A 48-Year-Old Woman with Recurrent Venous Thromboembolism and Pulmonary Artery Aneurysm.

Farber HW, McDermott S, Witkin AS, Kelly NP, Miloslavsky EM, Stone JR.

N Engl J Med. 2018 Apr 12;378(15):1430-1438. doi: 10.1056/NEJMcpc1800323. No abstract available.

PMID:
29641962
7.

Pulmonary Veno-Occlusive Disease: Welcome to the PAHty (Bostonian for Party).

Miller DP, Farber HW.

Circulation. 2017 Nov 21;136(21):2034-2036. doi: 10.1161/CIRCULATIONAHA.117.031158. No abstract available.

PMID:
29158214
8.

Using Clinical Trial End Points to Risk Stratify Patients With Pulmonary Arterial Hypertension.

Waxman AB, Farber HW.

Circulation. 2015 Dec 1;132(22):2152-61. doi: 10.1161/CIRCULATIONAHA.114.012328. Review. No abstract available.

PMID:
26621638
9.

Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).

Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, Hill NS, Farber HW.

Circulation. 2015 Dec 22;132(25):2403-11. doi: 10.1161/CIRCULATIONAHA.115.018435. Epub 2015 Oct 28.

Supplemental Content

Loading ...
Support Center